Table 1.
Comparative trials evaluating neoadjuvant pertuzumab
| Study | Phase | n | Treatment | pCR | EFS/DFS |
|---|---|---|---|---|---|
| Gianni et al [69] (NeoSphere) | II | 417 |
T/H T/HP HP T/P |
29% 46% 17% 24% |
81%* 84%* 80%* 75%* |
| Schneeweiss et al [70] (TRYPHAENA) | II | 225 |
FEC/HP + T/HP FEC + T/HP T/Cb/HP |
62% 57% 66% |
87%† 88%† 90%† |
| Nitz et al [71] (WSG-ADAPT) | II | 92 |
Pcl/HP HP |
90% 36% |
98%* 87%* |
| Hurvitz et al [72] (KRISTINE) | III | 444 |
T-DM1/P T/Cb/HP |
44% 55% |
85.3%† 94.2%† |
| van Ramshorst et al [73] (TRAIN-2) | III | 438 |
FEC/HP + Pcl/Cb/HP Pcl/Cb/HP |
67% 68% |
92.7%† 93.6%† |
| Swain et al [74] (BERENICE) | II | 397 |
AC + Pcl/HP FEC + Pcl/HP |
62% 61% |
90.8%* 89.2%* |
| Shao et al [75] (PEONY) | III | 329 |
T/HP T/H |
39% 22% |
84.8%* 73.7%* |
| Clark et al [76] (I-SPY2) | II | 128 |
T-DM1/P + AC Pcl/HP + AC Pcl/H + AC |
63% 72% 33% |
88%† 92%† 87%† |
| Tan et al [77] (FeDeriCa) | III | 500 |
AC + Tx/HP (SC) AC + Tx/HP (IV) |
60% 60% |
N/A N/A |
*at 5 years
†at 3 years
A, doxorubicine; C, cyclophosphamide; Cb, carboplatine; E, epirubicine; F, 5-fluorouracile; H, trastuzumab; IV, intravenous; Pcl, paclitaxel; P, pertuzumab; SC, subcutaneous; T-DM1, trastuzumab-emtansine; Tx, taxanes at investigator discretion; T, docetaxel